Deuterated amlexanox

• US 9,944,652 B2
• Filed: 05/12/2016
• Issued: 04/17/2018
• Est. Priority Date: 05/02/2013
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Saltiel, Alan R., Showalter, Hollis D., Larsen, Scott
• Primary Examiner(s): CHANDRAKUMAR, NIZAL S
• Application Number:
  US15/153,405
• Publication Number:
  US 20160251366A1
• Time in Patent Office: 705 Days
• Field of Search: 546 89
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: C07D 491/052 the oxygen-containing ring being six-membered

Abstract

Provided herein is technology relating to deuterated amlexanox and particularly, but not exclusively, to compositions comprising deuterated amlexanox, methods of producing deuterated amlexanox, and uses of deuterated amlexanox.

Claims

1. A composition comprising a deuterated amlexanox having a structure according to:

2. The composition of claim 1 wherein one or more of X, Y, or Z is enriched with deuterium more than 0.0200%.

3. The composition of claim 1 further comprising a pharmaceutically acceptable carrier, diluent, or excipient.

4. The composition of claim 1 wherein the deuterated amlexanox has a structure according to

5. The composition of claim 1 further comprising a TBK1 or a IKKϵ

kinase.

6. The composition of claim 1 further comprising a non-deuterated amlexanox or a pharmaceutically acceptable salt thereof.

7. The composition of claim 1 comprising a pharmaceutically effective amount of the deuterated amlexanox or the pharmaceutically acceptable salt thereof.

8. The composition of claim 1 formulated for administration to a human.

9. The composition of claim 1 further comprising a second pharmaceutical compound.

10. The composition of claim 1 wherein the pharmaceutically acceptable salt is a pharmaceutically acceptable salt of a compound having a structure according to